Like detectives working a cold case, scientists are using genes to unravel the mysteries of cancer’s origins and mutations, equipping doctors with new tools to target cancer at its source: the blunder coded in its molecular structure. Now, one groundbreaking clinical trial—the Targeted Agent and Profiling Utilization Registry (TAPUR™) Study—is revolutionizing our understanding of cancer at a cellular level. Led by the American Society of Clinical Oncology (ASCO), TAPUR is studying how commercially available anti-cancer drugs perform on a broader range of cancers, by matching the drugs to tumors with specific genomic mutations that the drugs are designed to target. Four years after the study’s launch, ASCO Chief Medical Officer Richard L., Schilsky, MD, FACP, FSCT, FASCO, sits down with our host, Pat Basu, MD, MBA, President & CEO of Cancer Treatment Centers of America® (CTCA), to share the strides TAPUR has made and how it’s impacted clinical trials on a global scale.